Glaukos slides as March investor deck reiterates guidance, offers few new catalysts
Glaukos shares fell about 4% as investors digested a newly filed March 2026 investor presentation that largely reiterates prior catalysts and 2026 sales guidance around a $610 million midpoint. With the stock recently volatile after earlier iDose TR and outlook-related moves, the lack of fresh upside surprises is weighing on sentiment.
1. What’s moving the stock
Glaukos (GKOS) is trading lower after the company posted an investor presentation in March 2026 tied to an SEC filing. The materials highlight recent iDose TR labeling changes and planned Epioxa commercialization activities, while reiterating 2026 sales guidance with a midpoint of roughly $610 million—information the market had largely been tracking already. (tradingview.com)
2. Why the market reaction is negative
After a run of sharp moves around earlier headline catalysts, a reiteration-heavy update can act like a “no new news” event for a high-expectations medtech name. The deck underscores long-duration iDose TR positioning (including repeat-treatment labeling) and Epioxa’s planned 1Q 2026 commercial launch activities, but it does not introduce a clear new upside driver that forces near-term estimate raises. (tradingview.com)
3. What matters next
Investors are likely to focus on evidence that iDose TR re-administration expands the addressable patient pool and on early commercial signals from Epioxa’s 2026 rollout. Any updates that shift the cadence of the 1Q 2026 launch activities, change the 2026 sales outlook, or quantify early uptake could quickly become the next catalyst for the stock. (tradingview.com)